163513-98-2

Basic information

• Product Name: (1R,4S)-TERT-BUTYL 2-OXO-7-AZABICYCLO[2.2.1]HEPTANE-7-CARBOXYLATE
• Synonyms: (1R,4S)-TERT-BUTYL 2-OXO-7-AZABICYCLO[2.2.1]HEPTANE-7-CARBOXYLATE;(1R,4S)-7-Boc-2-Oxo-7-azabicyclo[2.2.1]heptane;7-Azabicyclo[2.2.1]heptane-7-carboxylic acid, 2-oxo-, 1,1-diMethylethyl ester, (1R,4S)-;tert-butyl (1R,4S)-2-oxo-7-azabicyclo[2.2.1]heptane-7-carboxylate;(1R,4S)
• CAS NO: 163513-98-2
• Molecular Formula: C11H17NO3
• Molecular Weight: 211.259
• Mol File: 163513-98-2.mol
• Article Data: 31

Chemical Properties

• Boiling Point: 308.245°C at 760 mmHg
• Flash Point: 140.222°C
• Appearance: /
• Density: 1.174g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.515
• Storage Temp.: 2-8°C
• PKA: -1.82±0.20(Predicted)
• CAS DataBase Reference: (1R,4S)-TERT-BUTYL 2-OXO-7-AZABICYCLO[2.2.1]HEPTANE-7-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,4S)-TERT-BUTYL 2-OXO-7-AZABICYCLO[2.2.1]HEPTANE-7-CARBOXYLATE(163513-98-2)
• EPA Substance Registry System: (1R,4S)-TERT-BUTYL 2-OXO-7-AZABICYCLO[2.2.1]HEPTANE-7-CARBOXYLATE(163513-98-2)

Safety Data

• Hazardous Substances Data: 163513-98-2(Hazardous Substances Data)

Usage

General Description

The chemical "(1R,4S)-TERT-BUTYL 2-OXO-7-AZABICYCLO[2.2.1]HEPTANE-7-CARBOXYLATE" is a compound with a bicyclic structure containing a seven-membered ring with a nitrogen atom. It also contains a tert-butyl group and a carboxylate group. The compound is a carbamate derivative and belongs to the class of organic compounds known as azetidines. It can be used in the synthesis of pharmaceuticals or as a reagent in organic chemical reactions.

InChI:InChI=1/C11H17NO3/c1-11(2,3)15-10(14)12-7-4-5-8(12)9(13)6-7/h7-8H,4-6H2,1-3H3/t7-,8+/m0/s1

Upstream product

• 154905-39-2 (-)-exo-7-<(1,1-Domethylethoxy)carbonyl>-7-azabicyclo<2.2.1>heptan-2-ol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 182138-16-5 (1R,4S)-2-Oxo-7-aza-bicyclo[2.2.1]heptane-7-carboxylic acid benzyl ester 
• 254964-19-7 (1R,4S)-2-Vinylidene-7-aza-bicyclo[2.2.1]heptane-7-carboxylic acid tert-butyl ester 
• 635298-67-8 (1R,4R)-7-(tert-butoxycarbonyl)-7-azabicyclo[2.2.1]hept-5-en-2-one 
• 96894-00-7 (1S,2S)-4,4-ethylenedioxy-2-hydroxymethylcyclohexanol 
• 96893-99-1 (1R,2S)-5,5-(Ethylendioxy)-2-hydroxycyclohexancarbonsaeure-ethylester 
• 96817-54-8 ethyl (1R,2S)-2-acetoxy-5,5-ethylenedioxycyclohexanecarboxylate 
• 108963-96-8 (S)-1-tert-butoxycarbonyl-5-methoxycarbonyl-pyrrolidin-2-one 
• 78293-47-7 N-<(Trifluoroacetyl)amino>cyclohex-3-ene 
• 152533-42-1 N-Benzyl-N-cyclohex-3-enyl-2,2,2-trifluoro-acetamide 
• 152533-46-5 (±)-tert-butyl-(1SR,2RS,4RS)-2-hydroxy-7-azabicyclo[2.2.1]heptane-7-carboxylate 
• 1399823-13-2 (-)-(1R,4S)-tert-butyl 2-{(R)-tert-butylsulfinylimino}-7-azabicyclo[2.2.1]heptane-7-carboxylate 
• 154905-38-1 (+)-exo-7-<(1,1-Domethylethoxy)carbonyl>-7-azabicyclo<2.2.1>heptan-2-ol 

Downstream Products

• 140111-52-0 epibatidine 
• 152885-09-1 (+)-epibatidine hydrochloride 
• 152885-09-1 (-)-epibatidine hydrochloride 
• 163513-99-3 (1S,4R)-7-(tert-Butoxycarbonyl)-7-azabicyclo<2.2.1>heptan-2-one 
• 152614-12-5 tert-butyl (1R,2R,4S)-2-hydroxy-7-azabicyclo[2.2.1]heptane-7-carboxylate 
• 152533-46-5 (2-endo)-2-hydroxy-7-aza-bicyclo[2.2.1]heptane-7-carboxylic acid tert-butyl ester 
• 152533-46-5 (±)-tert-butyl-(1SR,2RS,4RS)-2-hydroxy-7-azabicyclo[2.2.1]heptane-7-carboxylate 
• 510748-36-4 tert-butyl 2-hydroxy-7-azabicyclo[2.2.1]heptane-7-carboxylate 
• 154905-39-2 (-)-exo-7-<(1,1-Domethylethoxy)carbonyl>-7-azabicyclo<2.2.1>heptan-2-ol 
• 152378-30-8 (-)-epibatidine 

Relevant articles and documents

The enantiomers of epiboxidine and of two related analogs: Synthesis and estimation of their binding affinity at α4β2 and α7 neuronal nicotinic acetylcholine receptors

Epiboxidine hydrochlorides (+)-2 and (-)-2, which are the structural analogs of the antipodes of epibatidine (-)-1, as well as the enantiomeric pairs (+)-3/(-)-3 and (+)-4/(-)-4 were synthesized and tested for binding affinity at α4β2 and α7 nicotinic acetylcholine receptor (nAChR) subtypes. Final derivatives were prepared through the condensation of racemic N-Boc-7-azabicyclo[2.2.1]heptane-2-one (±)-5 with the resolving agent (R)-(+)-2-methyl-2-propanesulfinamide. The pharmacological analysis carried out on the three new enantiomeric pairs evidenced an overall negligible degree of enantioselectivity at both nAChRs subtypes, a result similar to that reported for both natural and unnatural epibatidine enantiomers at the same investigated receptor subtypes.

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.

Substituted Imidazopyridines as HDM2 Inhibitors

The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Pd-catalyzed asymmetric β-hydride elimination en route to chiral allenes

We wish to report our preliminary results on the discovery and development of a catalytic, asymmetric β-hydride elimination from vinyl Pd(II)-complexes derived from enol triflates to access chiral allenes. To achieve this, we developed a class of chiral p